What is claimed:

1. Use of an effective amount of a population of placenta derived stem cells (PDSCs) comprising:

(a) CD10+PDSCs;

(b) CD34-PDSCs;

(c) CD105+PDSCs; and

(d) CD200+PDSCs,

in the manufacture of a composition for a method of ameliorating aging effects or correcting the proteomic and other defects associated with aging in a subject, which are selected from the group consisting of (a) a decline in physio-anatomic quality; (b) a reduced capacity to recover and repair following injury and/or disease; (c) decrease in skin elasticity; (d) diminished turgor in skin; (e) irregular skin texture; (f) irregular skin color; and (g) a diminished ability to repair after injury, the population of PDSCs is to be administered to the subject, wherein:

(i) the population of PDSCs maintains or increases the ratio of the number of stem cells to the number of differentiated cells in a tissue of a subject over time, wherein the ratio is maintained or increased over time as compared to the ratio of the number of stem cells to the number of differentiated cells in a tissue of a control subject over time; and

(ii) the population of PDSCs maintains or increases the number of stem cells in a tissue of a subject over time, , wherein the number of stem cells in the tissue of the subject is maintained or increased over time as compared to the number of stem cells in the same tissue of a control subject.

2. An *in vitro* method of:

(i) maintaining or increasing the number of endogenous stem cell in a tissue obtained from a subject over time, comprising administering to the tissue an effective amount of a population of placental derived stem cells (PDSCs), wherein the number of endogenous stem cells in the tissue is maintained or increased over time as compared to the number of endogenous stem cells in the same tissue of a control subject over time,

wherein the population of placental derived stem cells (PDSCs) comprises:

(a) CD10+PDSCs;

(b) CD34- PDSCs;

(c) CD105+PDSCs; and

(d) CD200+PDSCs.

3. The use of claim 1 or the method of claim 2, wherein the tissue is selected from the group consisting of muscle, brain, heart, kidney, liver, bone marrow, and skin.

4. The use of claim 1 or 3, or the method of any one of claims 2 to 3, wherein the control subject is the same subject before administration of the population of PDSCs or a subject that has not received the population of PDSCs.

5. The use claim 1 or 3, or the method of claim of any one of claims 2 to 3, wherein:

(i) the population of PDSCs is to be administered systemically, locally to the tissue, parenterally, intravenously, intramuscularly, subcutaneously, subdermally, intracompartmentally, by continuous drip, or as a bolus;

(ii) the population of PDSCs is prepared to be administered in an injectable liquid suspension or other biocompatible medium;

(iii) the population of PDSCs is to be administered using a catheter, a controlled-release system, or an implantable substrate or matrix;

(iv) the population of PDSCs is to be administered at a dose of between $1x10^5$ cells and $1x10^9$ cells, between $1x10^5$ cells and $1x10^7$ cells, or between $1x10^6$ cells and $1x10^7$ cells;

(v) the population of PDSCs is to be administered as a single dose or multiple doses;

(vi) the population of PDSCs is the first administration to the subject;

(vii) the population of PDSCs is to be administered when the subject is 10-15 years of age, 15-20 years of age, 20-25 years of age, 25-30 years of age, 30-35 years of age, 35-40 years of age, 40-45 years of age, 45-50 years of age, 50-55 years of age, 55-60 years of age, 60-65 years of age, 65-70 years of age, 70-75 years of age, 75-80 years of age, 80-85 years of age, 85-90 years of age, 90-95 years of age, 95-100 years of age, or over 100 years of age; or

(viii) the population of PDSCs is to be serially administered over the lifetime of the subject.

6. The use of any one of claims 1, and 3-5 or the method of claim 2, wherein the population of stem cells (i) consists essentially of PDSCs, or (ii) consists of PDSCs.

7. The use of any one of claims 1,and 3-6 or the method of claim 2, wherein the population of PDSCs:

(i) has previously been cryopreserved;

(ii) has been passaged at least three times;

(iii) has been passaged no more than ten times;

(iv) are from a placental stem cell bank;

(v) are embryonic-like stem cells;

(vi) are pluripotent or multipotent stem cells;

(vii) comprises cells obtained from a placenta that has been drained of cord blood; or

(viii) comprises cells obtained from a placenta that has been perfused to remove residual blood.

8. The use of any one of claims 1, and 3-7, or the method of claim 2, wherein

(i) the number of stem cells and/or differentiated cells in the tissue is determined before administration of the population of PDSCs to the subject, and

(ii) the number of stem cells and/or differentiated cells in the tissue is to be determined after administration of the population of PDSCs to the subject;

wherein optionally

(A) the population of PDSCs increases the number of stem cells in the tissue after administration as compared to before administration of the population of stem cells; or

(B) the subject has an increased number of stem cells as compared to a subject that has not received an administration of population of PDSCs, wherein the number of stem cells is assessed by stem cell colony forming units.

9. The use of any one of claims 1, and 3-8, or the method of claim 2, wherein the method further comprises culturing and/or expanding the population of PDSCs prior to administration to the subject, wherein

(i) the culturing and/or expanding is *in vitro* or in situ; or

(ii) the population of PDSCs is cultured and/or expanded in an extracorporeal device.